Source link : https://www.newshealth.biz/health-news/surrogate-endpoints-show-mixed-value-in-breast-cancer-trials/
TOPLINE: Pathologic complete response shows poor surrogacy for overall survival (OS) in neoadjuvant breast cancer (BC) trials, while invasive disease-free survival demonstrates moderate to strong association across multiple subgroups. Follow-up duration significantly impacts surrogacy value, with reliable forecasting achieved after 36-42 months. METHODOLOGY: Pathologic complete response and invasive disease-free survival are currently supported by regulatory […]
Author : News Health
Publish date : 2025-02-06 10:52:09
Copyright for syndicated content belongs to the linked Source.